Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally getting an FDA approval this year, it’s now turning to Tom ...
Lexicon (LXRX) Pharmaceuticals announced that the company has made the strategic decision to eliminate its commercial operations and rationalize resources across all functions in order to preserve ...
THE WOODLANDS, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following a strategic review of its commercial and pipeline programs, it ...
THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results